[{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therapeutics \/ Johnson & Johnson Innovative Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by i2o Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : This research collaboration underscores i2O’s mission to apply its Ionic Liquid platform towards the oral delivery of diverse payloads that can enable the wider adoption of much needed Macromolecules therapies for patients.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          June 01, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank